Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T21334 |
Bucillamine
DE-019,Thiobutarit,Tiobutarit,布西拉明,SA96,DE 019,DE019 |
VEGFR; Antioxidant | Angiogenesis; oxidation-reduction; Tyrosine Kinase/Adaptors |
Bucillamine (DE019) 可防止高危器官移植中的缺血/再灌注损伤,抑制 VEGF 的产生。 Bucillamine 是一种具有抗风湿和抗血管生成特性的口服活性巯基供体和抗氧化剂。 Bucillamine 可用于脉络膜新生血管和类风湿性关节炎的研究。 | |||
T23666 |
AGN-199659
AGN 199659,AGN199659 |
Others | Others |
AGN-199659 is a novel tyrosine kinase inhibitor. It also blocks choroidal neovascularization. | |||
T69479 |
CGC 11093
|
Others | Others |
CGC 11093 is a polyamine analog; inhibits growth of human prostate tumor xenografts in nude mice. It may prove useful in promoting regression of choroidal neovascularization. | |||
T36718 |
Tie2 Inhibitor 7
|
Others | Others |
Tie2 Inhibitor 7 blocks Tie2 kinase activity with a Ki value of 1.3 μM.. It has been shown to inhibit angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling with an IC50 value of 0.3 μM. This compound can prevent endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization. | |||
T35494 |
(±)11(12)-EET
|
Others | Others |
(±)11(12)-EET is a fully racemic version of the R/S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.[1][2][3[]A higher proportion of 11(R),12(S)-EET is produced by the CYP450 isoforms CYP2C23 and CYP2C24 while CYP2B2 produces a higher proportion of 11(S),12(R)-EET.[3]11(12)-EET has been shown, along with 8(9)-EET to play a role in the recovery of depleted calcium pools in cultured smooth muscle cells[4] It also inhibits basolateral 18-pS potassium channels in t... |